Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05748171

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

Sex: All

Ages: 1 Year – 17 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 100

Sponsor: Pfizer

Location: St. Anna Kinderspital Vienna

Summary

This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \

Eligibility Criteria

Inclusion Criteria: 1. Male or female participants between 1 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05748171). StuddyBuddy aggregates publicly available trial information.